摘要
目的探讨参苓白术加味汤联合化疗治疗非小细胞肺癌的效果和安全性及对患者血清血管内皮生长因子(VEGF)、基质金属蛋白酶-9(MMP-9)表达的影响。方法选择60例非小细胞肺癌患者,随机分为联合组和对照组,各30例,联合组给予参苓白术加味口服联合常规化疗方案治疗,对照组给予单纯常规化疗方案治疗,比较两组近期疗效,血清VEGF、MMP-9水平的变化和不良反应。结果联合组临床获益率与对照组比较,差异有统计学意义(χ2=4.924,P<0.05)。治疗后CR+PR、SD、PD患者血清VEGF、MMP-9水平与治疗前比较,差异均有统计学意义(F=5.168、5.698,均P<0.05)。治疗后联合组血清VEGF、MMP-9水平与对照组比较,差异均有统计学意义(t=4.982、6.219,均P<0.05),联合组Karnofsky评分及生活质量改善效果与对照组比较,差异有统计学意义(t=5.468,P<0.05;χ2=6.852,P<0.05),不良反应均较对照组轻(χ2=4.628、4.168、3.986、4.462,均P<0.05)。结论参苓白术加味汤有效提高VEGF、MMP-9表达,提高非小细胞肺癌化疗患者临床获益和生活质量,安全性较高。
Objective To investigate the effect and safety of Shenling Baizhu Modified Decoction combined with chemotherapy for patients with non-small cell lung cancer and the influence on expression of serum vascular endothelial growth factor （VEGF） and matrix metalloproteinase-9 （MMP-9）. Methods 60 patients with non-small cell lung cancer were selected and randomly assigned into combination group and control group, 30 cases respectively. The combination group was treated by Shenling Baizhu Modified Decoction combined with conventional chemotherapy, while the control group was treated by con- ventional chemotherapy alone. The short-term effect, changes of serum level of VEGF and MMP-9, and adverse reaction in both groups were compared. Results The comparison of the rate of clinical benefit in both groups showed statistically signifi- cant difference （χ2=4.924, P 〈 0.05）. The comparison of CR＋PR, SD, PD, and serum levels of VEGF and MMP-9 of patients be- fore and after treatment showed statistically significant difference （F = 5.168, 5.698, all P 〈 0.05）. After treatment, the serum lev- els of VEGF and MMP-9 in combination group showed statistically significant difference （t = 4.982, 6.219, all P 〈 0.05） com- pared with those of control group; the Karnofsky score and improved effect of life quality in combination group showed statisti- cally significant difference （t = 5.468, P 〈 0.05; χ2=6.852, P 〈 0.05） compared with those of control group; the adverse reactions in combination group were milder than those of control group （χ2=4.628, 4.168, 3.986, 4.462, all P 〈 0.05）. Conclusion Shenling Baizhu Modified Decoction can effectively enhance the expression of VEGF and MMP-9, improve clinical benefit and life quality of patients with non-small cell lung cancer received chemotherapy, and has higher safety.
出处
《中国医药导报》
CAS
2013年第29期72-75,共4页
China Medical Herald
基金
湖北省荆州市医疗卫生科技发展计划项目(项目编号:荆科技发[2011]13号027)
关键词
非小细胞肺癌
化疗
参苓白术加味汤
中药
血管内皮生长因子
基质金属蛋白酶-9
Non-small cell lung cancer
Chemotherapy
Sheuling Baizhu Modified Decoction
Traditional Chinese medicine
Vascular endothelial growth factor
Matrix metalloproteinase-9
